GlobeNewswire

Nasdaq to Move Global Headquarters to 4 Times Square

Dela
The Company Signs 145,000 Square Foot Lease with The Durst Organization at 4 Times Square

A new 10th floor, outdoor terrace will be created above the world-famous Nasdaq Tower overlooking Times Square

NEW YORK, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (NASDAQ:NDAQ) today announced it is relocating its global headquarters from downtown Manhattan to its current Nasdaq MarketSite location at The Durst Organization's 4 Times Square. Highlights of the new agreement include the following:

  • The deal with The Durst Organization more than quintuples Nasdaq's existing footprint at the property. 
  • The 10th floor will be home to a state-of-the-art event space as an extension of the Nasdaq MarketSite and feature a 2,100 square foot outdoor terrace overlooking Times Square, above the world-famous Nasdaq Tower, for Nasdaq clients and prospects with the capacity to host more than 400 people for corporate events.
  • The 15-year lease for 145,000 square feet, includes an extension of the current 24,000 square foot MarketSite lease.  

"Since our beginning, Nasdaq has played a major role in the growth of corporate America by providing a seamless platform to raise capital through the public markets. Throughout the decades, we have expanded our business and brand globally and our technology now powers more than 90 marketplaces around the world," said Adena Friedman, President and Chief Executive Officer, Nasdaq. "Bringing together our New York employees at our new headquarters allows us to continue to focus on the client experience and further collaborate as a team on new and innovative solutions that meet our clients' most critical needs.  This increased presence in the iconic Times Square, New York, will further drive our brand forward, and will offer an unparalleled experience for our clients for years to come."

"As one of the building's original tenants when it opened in 1999, we are pleased Nasdaq has chosen to consolidate their corporate headquarters, and bring their leadership team, to 4 Times Square," said Jonathan (Jody) Durst, President of The Durst Organization. "Nasdaq is one of the world's most innovative and dynamic exchanges and a recognized global leader in financial technology, and we are excited they have decided to continue to partner with us and grow their business for the 21st Century at 4 Times Square." 

Nasdaq's new global headquarters will remain the center for companies that want to take advantage of its world class location which includes:

  • The Opening and Closing Market Bell ceremonies at the Nasdaq MarketSite in New York City's Times Square;
  • The Nasdaq MarketSite has an exclusive event space that will expand to host a variety of corporate and industry events;
  • Recently enhanced broadcast and media correspondence facilities allow for company brand and executive visibility strategies through organized interviews and press briefings with global news outlets;
  • Multiple Nasdaq Tower and Nasdaq Marquee advertising opportunities; and,
  • The home to the Market Intelligence Desk that consists of a team of market professionals, all working to keep clients on top of the market with up-to-the-minute analysis and information. 

The three-year MarketSite expansion and relocation initiative will commence construction this summer and is slated for completion in December 2021, with phased move-ins beginning in spring 2019.

4 Times Square has recently undergone a $140 million capital improvement program.  The 45,600 square foot amenity floor, featuring a café and coffee bar run by Michelin Star Chef Claus Meyer and first-class conference, meeting and event spaces managed by Convene, will open to tenants and their guests later this year.

The Durst Organization has already leased over half of the space formerly occupied by Condé Nast.  The Nasdaq deal marks the first of the building's upper floors to be leased prior to Skadden, Arps, Slate, Meagher & Flom's departure in 2020.

About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $13 trillion. To learn more, visit: http://business.nasdaq.com.

About The Durst Organization

The Durst Organization, founded in 1915 by Joseph Durst, is the owner, manager and builder of 13 million square feet of premiere Manhattan office towers and 1,950 residential rental units with 3,400 in development. The Durst Organization is recognized as a world leader in the development of high-performance and environmentally advanced commercial and residential buildings.  www.durst.org

NDAQG

CONTACT:
Jordan Barowitz
The Durst Organization
212/257-6605
jbarowitz@durst.org

Allan Schoenberg
Nasdaq, Inc
212/231-5534
allan.schoenberg@nasdaq.com

Emily Pan
Nasdaq, Inc
646/441-5120
emily.pan@nasdaq.com

Photos accompanying this announcement are available at:

http://www.globenewswire.com/NewsRoom/AttachmentNg/f14e710f-29ec-4143-a46d-e0fffaf11f37

http://www.globenewswire.com/NewsRoom/AttachmentNg/8220fa17-9c63-43c5-a361-dd164a9b41e5

http://www.globenewswire.com/NewsRoom/AttachmentNg/6cc6d1d2-9912-4869-8b4b-caec03ff1294

http://www.globenewswire.com/NewsRoom/AttachmentNg/01206e0e-1288-4c95-a130-480b65427656

 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nasdaq via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin22.2.2019 08:00:00Pressmeddelande

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy adults. Modus Therapeutic develops sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) - a painful, inherited blood disorder affecting millions of people around the globe. Sevuparin has the potential to improve the SCD patients' blood flow reducing their pain and the amount of time they will need to spend in hospital. Intravenously administered sevuparin is currently being tested in a phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. In order to broaden sevuparins potential to help SCD patients outside of the hospital setting, Modus Therapeutics in parallel explores subcutaneously administered sevuparin. The first cohort in a

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin22.2.2019 08:00:00Pressmeddelande

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy adults. Modus Therapeutic develops sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) - a painful, inherited blood disorder affecting millions of people around the globe. Sevuparin has the potential to improve the SCD patients' blood flow reducing their pain and the amount of time they will need to spend in hospital. Intravenously administered sevuparin is currently being tested in a phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. In order to broaden sevuparins potential to help SCD patients outside of the hospital setting, Modus Therapeutics in parallel explores subcutaneously administered sevuparin. The first cohort in a

Arcomas CFO lämnar bolaget21.2.2019 23:50:00Pressmeddelande

Arcomas CFO, AnnaPia Johansson har valt att avsluta sin tjänst för nya utmaningar utanför Arcoma. AnnaPia arbetar oförändrat vidare i sin nuvarande tjänst fram till augusti månad eller tills att en ersättare har rekryterats. "Jag vill tacka AnnaPia för hennes ambitiösa arbete för Arcoma och samtidigt önska henne lycka i framtida utmaningar " säger Jesper Söderqvist, VD Arcoma. Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade i hela världen. Arcoma är listat på Nasdaq First North. Certified Advi

Corline Biomedical AB offentliggör bokslutskommuniké för räkenskapsåret 201821.2.2019 08:45:00Pressmeddelande

Corline Biomedical AB ("Corline") publicerar härmed bokslutskommuniké för det fjärde kvartalet och räkenskapsåret 2018. Nedan följer en kort sammanfattning. Fullständig bokslutskommuniké finns tillgänglig på Corlines hemsida (www.corline.se) samt som bifogad fil. VD Henrik Nittmar kommenterar "2018 blev ett genombrottsår för Corline då bolaget gick från preklinisk till klinisk fas i utvecklingen av Renaparin® i och med att RENAPAIR 01-studien öppnade för rekrytering. Nu koncentrerar vi utvecklingsresurserna på att planera inför den värdehöjande fas 2- och fas 3-utvecklingen. Jämfört med branschkollegor har Corline en särskilt gynnsam position i och med att bolaget står på flera ben och parallellt arbetar mot lansering tillsammans med kunder inom medicinteknikområdet. Ett spännande 2019 stundar." Väsentliga händelser under det fjärde kvartalet 2018 Den vetenskapliga tidskriften Transplantation publicerar resultat från den prekliniska utvecklingen av Renaparin®. Här visas i stordjursmode

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum